Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct Phase 3 Study of Ifenprodil for COVID-19

VANCOUVER, British Columbia, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc.A (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the a??Companya?? or a??Algernona??) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (a??DSMBa??) has completed its latest review of the Phase 2b part of the Companya??s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study.
The DSMB is a committee of clinical research experts, including physicians, statisticians, and patient advocates, who are monitoringA the progress of the Companya??s clinical trial, and are reviewing safetyA and effectiveness dataA while the trial is ongoing.a??While we await final data from the Phase 2b part of our Ifenprodil COVID-19 study, it is critical for us to know that from a safety perspective, we are now clear to move into the Phase 3 part of the study,a?? said Christopher J. Moreau, CEO of Algernon Pharmaceuticals.The Company is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.About NP-120 (Ifenprodil)
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Март 2021    »